Litcius/Paper detail

Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm

Douglas Tremblay, Jonathan Feld, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, Marina Kremyanskaya, Michal Bar‐Natan, Alan H. Shih, Alla Keyzner, John Mascarenhas

2020Leukemia Research29 citationsDOI

Topics & Concepts

Myeloproliferative neoplasmVenetoclaxMyeloid leukemiaMedicineHypomethylating agentNeoplasmLeukemiaMyeloproliferative DisordersMyeloidOncologyInternal medicineCancer researchMyelofibrosisPathologyBone marrowBiologyDNA methylationGeneBiochemistryChronic lymphocytic leukemiaGene expressionAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia Treatments
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm | Litcius